Literature DB >> 37091

The effect of rifampicin on norethisterone pharmacokinetics.

D J Back, A M Breckenridge, F Crawford, M MacIver, M L Orme, B K Park, P H Rowe, E Smith.   

Abstract

The pharmacokinetics of norethisterone have been studied in 8 women during and one month after treatment with rifampicin (450--600 mg/day). Rifampicin caused a significant reduction in the A.U.C. of a single dose of 1 mg norethisterone from 37.8 +/- 13.1 to 21.9 +/- 5.9 ng/ml X h (p less than 0.01). The plasma norethisterone half life (beta-phase) was also reduced from 6.2 +/- 1.7 to 3.2 +/- 1.0 h (p less than 0.0025). In one additional woman on long term oral contraceptive therapy the 12 hour plasma norethisterone concentration was reduced by rifampicin from 12.3 ng/ml to 2.3 ng/ml. Rifampicin caused a significant increase in antipyrine clearance, 6 beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity but there was no significant correlations between changes in these indices of liver microsomal enzyme induction. There was a significant correlation between the percentage increase in antipyrine clearance and the percentage decrease in norethisterone A.U.C. during rifampicin. The changes in norethisterone pharmacokinetics during rifampicin therapy are compatible with the known enzyme inducing effect of rifampicin.

Entities:  

Keywords:  Biology; Clinical Research; Estrogens; Follow-up Studies; Hepatic Effects; Laboratory Procedures; Oral Contraceptives; Physiology; Research Methodology; Studies; Women

Mesh:

Substances:

Year:  1979        PMID: 37091     DOI: 10.1007/bf00563105

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma.

Authors:  R H SILBER; C C PORTER
Journal:  J Biol Chem       Date:  1954-10       Impact factor: 5.157

2.  Antipyrine: radioimmunoassay in plasma and saliva following administration of a high dose and a low dose.

Authors:  R L Chang; A W Wood; W R Dixon; A H Conney; K E Anderson; J Eiseman; A P Alvares
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

3.  Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

4.  [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].

Authors:  L Nocke-Finck; H Breuer; D Reimers
Journal:  Dtsch Med Wochenschr       Date:  1973-08-11       Impact factor: 0.628

5.  [Rifampicin and oral contraceptives (author's transl)].

Authors:  R Kropp
Journal:  Prax Pneumol       Date:  1974-05

6.  [Letter: Sleeping pills].

Authors:  A Hirsch
Journal:  Nouv Presse Med       Date:  1973-12-08

7.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

8.  A kinetic photometric method for serum gamma-glutamyl transpeptidase.

Authors:  G Szasz
Journal:  Clin Chem       Date:  1969-02       Impact factor: 8.327

9.  Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol.

Authors:  S E Smith; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

10.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

View more
  15 in total

1.  Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.

Authors:  F A Pieters; F Woonink; J Zuidema
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

3.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 5.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 6.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

7.  Antibiotic and oral contraceptive drug interactions: Is there a need for concern?

Authors:  G G Zhanel; S Siemens; K Slayter; L Mandell
Journal:  Can J Infect Dis       Date:  1999-11

Review 8.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 9.  The third S.K. & F. Prize lecture, University of London, December 1981. The clinical pharmacology of oral contraceptive steroids.

Authors:  M L Orme
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

10.  Drug interaction with oral contraceptive steroids.

Authors: 
Journal:  Br Med J       Date:  1980-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.